Immune Therapy and Immune Modulation Workshop

JAMES W. HODGE, Ph.D., MBA
SAMIR KHLEIF, MD
MARKA CRITTENDEN, MD, Ph.D.
MARK EINSTEIN, MD

Friday, July 17th, 2015
Sheraton Denver Downtown
11:00 am – 12:30 pm

Theme: 'Trial Design Focus: T-cell Clonality to Predict Patient Responses to Immunotherapy'

Precis': The utilization of immunotherapy has significantly improved the overall survival of many cancer patients. However, a correlative immune biomarker associated with increased overall survival has yet to be identified. There has been a critical need to be able to identify which patients are responding to immunotherapy combinations as well as correlate these observations with clinical response. This session will focus on emerging clinical data analyzing changes in T-cell clonal populaitons following immunotherapy.

3 Speakers:

Tracking immune response in patients receiving immunotherapies.
Lawrence Fong, M.D. Professor, Department of Medicine, Principle Investigator, UCSF School of Medicine. San Francisco, CA. LRobert@mednet.ucla.edu

Melanoma: Can clonality help predict response to immune checkpoint blockade?
Lidia Robert, Ph.D., Division of Hematology-Oncology, UCLA Medical Center, Los Angeles, CA. Lawrence.Fong@ucsf.edu

Company Perspective: Immunosequencing: Unveiling New Molecular Biomarkers for Immunotherapy.
Catherine Sanders, Scientific Liaison, Adaptive Biotechnologies Corp.
csanders@adaptivebiotech.com